How to grasp the future of hepatitis C?

Due to the relative stability of foreign markets, major foreign pharmaceutical companies have turned their attention to the huge market of China. Many new anti-HCV drugs have been submitted for registration in China, and major HCV pharmaceutical giants are laying out the China market. At present, there is a hepatitis C product "Dalatavir hydrochloride tablets combined with Ashouwei soft capsules" listed in China, and it is also the only one at present. Enterprises that independently research and develop new drugs for hepatitis C in China will face many challenges in the future. In terms of imitation, domestic generic drug companies are not far behind, and dozens of domestic companies have applied for generic drugs of sofebuvir. Due to patent restrictions, these generic drugs cannot be approved for listing before 2024, so the initial hepatitis C market is still dominated by multinational products. Due to the high procurement cost of the original drug, it is difficult to support the national medical insurance and it is unlikely to enter the medical insurance. These products should be covered by medical insurance. Unless the price is greatly reduced or generic drugs are listed after the patent expires, there is a great possibility that generic drugs will occupy the China market in the future. Of course, it remains to be seen whether the original drugs or generic drugs can seize the China market.